Serina Therapeutics (SER) Proxy filing summary

Executive summary

• Annual meeting scheduled for November 7, 2025, with virtual attendance available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by November 6, 2025.

Voting matters and shareholder proposals

• Election of two Class II directors to serve until the 2028 annual meeting: Steve Ledger and Karen J. Wilson.

• Ratification of Frazier & Deeter, LLC as independent registered public accountants for fiscal year ending December 31, 2025.

• Approval of issuance of common stock related to the exercise of certain existing Convertible Note and Warrants, in accordance with NYSE American listing rules.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director nominees and auditor ratification.